Curanex Pharmaceuticals Inc Leases Disclosure
5. Lease
On January 1, 2025, the Company assumed an office lease from Duraviva Pharma Inc. (“Duraviva”), a New York corporation under common control, through a lease assignment agreement. The lease term extends through August 31, 2026. The Company classified the lease as an operating lease. Upon adoption of ASC 842, the Company recognized right-of-use asset and corresponding lease liability for its operating lease.
During the fourth quarter of 2025, the Company entered into lease agreements for three motor vehicles with non-cancelable terms ranging from 36 to 51 months.
The following summarizes information about the Company’s lease as of December 31, 2025 and 2024.
| For
the Years Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Amount recognized in the income statements | ||||||||
| Operating lease expense | $ | 88,040 | $ | |||||
| As of December 31, 2025 | As of December 31, 2024 | |||||||
| Amount recognized in the balance sheets | ||||||||
| Right-of-use assets | $ | 352,616 | $ | |||||
| Operating lease liabilities | 346,699 | |||||||
| Amount recognized in the income statements | ||||||||
| Operating lease expense | $ | 88,040 | $ | |||||
| Cash paid for amounts included in the measurement of lease liabilities | ||||||||
| Operating lease expense | $ | 93,957 | $ | |||||
| Lease commitment | ||||||||
| 2026 | $ | 136,921 | $ | |||||
| 2027 | 89,964 | |||||||
| 2028 | 86,766 | |||||||
| 2029 | 61,078 | |||||||
| Total future minimum lease payments | 374,729 | |||||||
| less imputed interest | (28,030 | ) | ||||||
| Present value of lease liabilities | $ | 346,699 | $ | |||||
| Supplement information | ||||||||
| Discount rate | 5.47 | % | n.a. | |||||
| Remaining lease term | 47 months | n.a. | ||||||
Want the next Curanex Pharmaceuticals Inc leases disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Curanex Pharmaceuticals Inc's next filing hits EDGAR. No credit card, your email never gets sold.
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.